Myelin News and Research

RSS

Myelin is the fatty substance that covers and protects nerves.

Synthetic peptide repairs, regenerates stroke-injured brain tissue

A synthetic version of a naturally occurring peptide promoted the creation of new blood vessels and repaired damaged nerve cells in lab animals, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended March 31, 2010 and provided an update on its corporate developments.

14 May 2010

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

A National Institutes of Health grant will help University of Central Florida researchers explore new ways to potentially reverse the damage caused by multiple sclerosis and other neurological disorders.

11 May 2010

Bone marrow stem cells show promise in multiple sclerosis

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

New test indicates bone marrow cell therapy may benefit MS patients

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring StemCells Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010

Tel Aviv scientist uncovers a new way of detecting multiple sclerosis

Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled. Among its high-profile victims are celebrated cellist Jacqueline du Pre, whose career was ended by MS, and Joan Didion, one of America's greatest writers - but they are far from alone.

30 Apr 2010

Mayo Clinic study finds changes in tissue damage throughout the course of MS

A new Mayo Clinic study has found that the type of tissue damage changes throughout the course of multiple sclerosis. In early relapsing disease stages, the plaques, or areas where the nervous system is inflamed or demyelinated, are predominantly active with distinct heterogeneous patterns of myelin damage.

23 Apr 2010

OECs may hold promise for pediatric cerebral palsy treatment

A unique cell type that supports and surrounds (ensheathes) neurons within the nose (olfactory system) known as olfactory ensheathing cells (OECs), possess the ability to regenerate, are relatively easy to obtain, and have become prime candidates for transplantation to repair a number of lesions in the central nervous system (CNS).

19 Apr 2010

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range.

16 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

Study combines CT and VBM to provide accurate picture of autistic brain

A new study, the first of its kind, combines two complementary analytical brain imaging techniques, to provide a more comprehensive and accurate picture of the neuroanatomy of the autistic brain. The study, published in the April issue of neuroimaging journal Human Brain Mapping, was conducted by researchers at The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the Universit- de Montr-al.

15 Apr 2010

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

Transgenic mouse model study confirms passage of maternal thyroid hormones to fetus

Until now there were only indirect evidence of the transfer of thyroid hormones from mother to fetus through the placenta during pregnancy. That event is very important because the maternal thyroid hormones appear to play a key role in the development of the nervous system and other organs of the fetus; so it's true that in case of maternal thyroid disease, such hypothyroidism, have a direct bearing on the unborn child with reduction, also significant, to its Q.I..

12 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Myelin News and Research

Further Reading

Synthetic peptide repairs, regenerates stroke-injured brain tissue

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

Bone marrow stem cells show promise in multiple sclerosis

New test indicates bone marrow cell therapy may benefit MS patients

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

Tel Aviv scientist uncovers a new way of detecting multiple sclerosis

Mayo Clinic study finds changes in tissue damage throughout the course of MS

OECs may hold promise for pediatric cerebral palsy treatment

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

Study: Atorvastatin may slow down MS progression

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Study combines CT and VBM to provide accurate picture of autistic brain

Opexa Therapeutics presents key efficacy data on Tovaxin

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Transgenic mouse model study confirms passage of maternal thyroid hormones to fetus

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Dalfampridine drug for multiple sclerosis now available in the U.S.

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News